Particle.news
Download on the App Store
10 ARTICLES
·
3mo ago

AstraZeneca Reports Q1 Growth and Expands US Investments Amid Regulatory Challenges

The pharmaceutical giant posts 10% revenue growth, accelerates US manufacturing and R&D plans, and faces legal scrutiny in China over tax and data issues.

(FILES) A general view taken on February 8, 2022 shows the AstraZeneca facility for biological medicines in Södertälje, south of Stockholm, Sweden. British pharmaceutical giant AstraZeneca on April 29, 2025 vowed to keep investing and growing its business in the United States, ahead of President Donald Trump's possible tariffs on the sector. (Photo by Jonathan NACKSTRAND / AFP) (Photo by JONATHAN NACKSTRAND/AFP via Getty Images)
The logo of the British pharmaceutical company AstraZeneca is seen at the company's China Commercial Innovation Centre (CCIC) in Wuxi, Jiangsu province, China, September 15, 2018. Picture taken September 15, 2018. REUTERS/Adam Jourdan
A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble
Image

Overview

  • AstraZeneca reported a 10% increase in Q1 2025 revenue to $13.6 billion, driven by strong performance in oncology and biopharmaceuticals.
  • The company reaffirmed its $80 billion annual revenue target by 2030, citing progress in its drug pipeline and global growth strategy.
  • Amid a US national security investigation into pharmaceutical imports, AstraZeneca announced expanded investments in US manufacturing and R&D facilities in Maryland and Massachusetts.
  • In China, the company is under investigation for $1.6 million in alleged unpaid import taxes and potential data infringement, which could result in significant fines.
  • AstraZeneca continues to navigate fallout from the arrest of its former China president and employee convictions for insurance fraud tied to its cancer drug Tagrisso.